Jump Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

Jump Financial’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$395K	Buy	+15,600	New	+$343K	﹤0.01%	1558
2026 Q1	–	Sell	-108,355	Closed	-$2.89M	–	1826
2025 Q4	$2.89M	Buy	+108,355	New	+$2.59M	0.04%	546
2025 Q1	–	Sell	-154,006	Closed	-$2.83M	–	1545
2024 Q4	$2.83M	Sell	154,006 -12,382	-7%	-$200K	0.06%	415
2024 Q3	$2.56M	Buy	166,388 +124,618	+298%	+$2.08M	0.05%	425
2024 Q2	$679K	Sell	41,770 -107,233	-72%	-$1.73M	0.01%	990
2024 Q1	$2.76M	Buy	149,003 +32,662	+28%	+$809K	0.07%	317
2023 Q4	$3.64M	Buy	116,341 +89,053	+326%	+$2.13M	0.12%	187
2023 Q3	$569K	Sell	27,288 -50,401	-65%	-$1.37M	0.02%	956
2023 Q2	$1.86M	Sell	77,689 -119,221	-61%	-$2.65M	0.07%	419
2023 Q1	$3.71M	Buy	+196,910	New	+$3.75M	0.15%	216
2022 Q4	–	Sell	-13,100	Closed	-$214K	–	1521
2022 Q3	$214K	Sell	13,100 -127,669	-91%	-$2.07M	0.01%	1317
2022 Q2	$1.98M	Buy	140,769 +74,525	+113%	+$1.39M	0.09%	318
2022 Q1	$1.6M	Buy	+66,244	New	+$1.6M	0.07%	344
2021 Q3	–	Sell	-79,060	Closed	-$1.93M	–	1052
2021 Q2	$1.93M	Buy	+79,060	New	+$1.78M	0.19%	114

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jump Financial's ACAD Position: Q2 2026 in Review

Jump Financial opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 15,600 shares worth $395K. The stake represents ﹤0.01% of the portfolio and ranks #1558 among its holdings. This is a return to the name: Jump Financial previously reported a position in ACAD as recently as Q4 2025.

Jump Financial first reported a position in ACAD in Q2 2021 and has held it in 14 quarters since. The position peaked at $3.71M in Q1 2023. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Jump Financial held 15,600 shares of Acadia Pharmaceuticals worth $395K as of Q2 2026.
Acadia Pharmaceuticals was a new Jump Financial position in Q2 2026.
Acadia Pharmaceuticals made up ﹤0.01% of Jump Financial's portfolio in Q2 2026, its #1558 holding.
Jump Financial first reported a position in Acadia Pharmaceuticals in Q2 2021 and has held it in 14 quarters since.
Jump Financial's Acadia Pharmaceuticals position peaked at $3.71M in Q1 2023.
352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.